After solid-phase synthesis, a crude peptide is a mixture of the target sequence with deletion, truncated, and partially deprotected impurities. This guide explains the standard RP-HPLC purification workflow with C18 and 0.1% TFA, when countercurrent distribution is worth using, and how continuous…
After solid-phase peptide synthesis SPPS , cleavage from the resin yields a crude product, and purification is the step that decides whether a target purity is reachable at acceptable cost. Three methods matter in practice: reverse-phase HPLC, which is the standard; countercurrent distribution, which serves solution-phase and difficult peptides; and MCSGP, a continuous chromatographic process aimed at production scale. This guide covers what each method does, what the evidence behind the claimed performance figures actually shows, and how a manufacturer should choose among them.
The crude material from an SPPS run contains the desired peptide plus a predictable set of contaminants: deletion peptides, truncated peptides, incompletely deprotected peptides, modified peptides, residual reagents, and by-products from cleaved protecting groups. Peptide behavior is determined by amino acid composition and sequence, which means an impurity that is the target sequence minus one residue, or the target sequence still carrying part of a protecting group, can be very close to the product in size, charge, and hydrophobicity. Purification methods therefore work on small differences in physical chemistry, not on recognition of the correct sequence.
The crude also carries processing chemicals. Cytotoxic reagents used during chain assembly are removed by washing the resin before final cleavage or by the purification itself, with one exception: trifluoroacetic acid TFA . TFA is the cleavage and deprotection acid and is present at high concentration, but it is not handled as a cytotoxic reagent that must be washed away; it is removed by evaporation. It matters later because it ends up as the counterion of the final peptide salt.
Purification becomes a bottleneck in large-scale production precisely when crude quality is poor. A process that is economical with a 95% pure crude can become uneconomical with an 80% pure one, not because the chromatography runs worse but because the load of closely related impurities is higher and the yield at target purity falls.
This impurity profile is specific to chemical synthesis. Recombinant expression makes peptides by translation, so deletion sequences are not generated the way they are in SPPS; the purification problem shifts to host-cell proteins, tag cleavage, and release of the correct N-terminus. The indexed literature reflects that difference. Reviews catalog affinity tags for single proteins and multi-protein complexes PMID 32504500 and aggregating tags for column-free purification PMID 26556016 . A review of recombinant hypocholesterolemic peptides presents genetic engineering as a distinct preparative route with its own purification demands PMID 25214222 . A 2024 study fused human superoxide dismutase to a resilin-like polypeptide tag and purified it with 1.5 M ammonium sulfate precipitation and a 60 °C heat step, recovering 80% of enzyme activity with up to 24-fold purification, and the tagged protein proved more stable than the His-tagged variant under thermal, pH, and storage stress PMID 38901714 . A cleavable self-aggregating tag strategy for the therapeutic peptide GLP-1 uses pH-induced intein self-cleavage to produce an authentic N-terminus at about 4.4 µg per mg of wet cell pellet PMID 35089554 . These are different problems solved by different tools. For chemically synthesized peptides, the tool is chromatography, and the default is reverse-phase HPLC .
Reverse-phase HPLC is the standard method for purifying synthetic peptides. The most common configuration uses C18-modified silica as the stationary phase: octadecyl chains bonded to silica particles. The mobile phase starts as water containing 0.1% TFA , and a gradient raises the proportion of acetonitrile, which also contains 0.1% TFA . At the low pH set by TFA, the basic side chains of arginine, lysine, and histidine, and the N-terminus itself, are protonated, and trifluoroacetate acts as an ion-pairing agent that increases retention on the hydrophobic surface. Retention is therefore governed by hydrophobicity: more hydrophobic peptides and impurities bind more strongly.
Polar contaminants, including hydrophilic reagents, salts, and short hydrophilic fragments, elute first under the aqueous start conditions. As the acetonitrile fraction rises, the mobile phase becomes less polar, the target peptide desorbs, and more hydrophobic impurities follow. The column effluent is monitored by UV absorbance at 210-220 nm . Aromatic residues absorb at 280 nm, but a peptide lacking tryptophan or tyrosine is nearly invisible there, whereas the amide bond itself absorbs in the 210-220 nm range, which is why that window is used. Fractions are collected across the product peak and checked by analytical HPLC; only fractions judged sufficiently pure are pooled. Preparative columns are deliberately loaded beyond their analytical resolution limits, which broadens peaks and makes the analytical check of every fraction mandatory. The pooled solution is then freeze-dried, or lyophilized , to a fine white powder. Lyophilization cannot remove all residual water, but the water that remains does not affect the final product.
Two features of this workflow are easy to overlook. The first is the salt problem. Because TFA is the cleavage acid, the mobile phase ion-pairing agent, and a counterion for basic groups N-terminus, arginine, lysine, histidine , Fmoc-synthesized peptides typically end up as TFA salts. Acetate salts appear when acetate is used in the final step instead. Both salt forms survive purification and do not affect final quality, and there is no point trying to strip them. For anyone buying peptide material, the practical implication is to compare products by peptide content stated on the certificate of analysis, not by dry weight, because the powder includes counterion and residual water.
The second is the meaning of sufficient purity. The standard method does not fix the analytical HPLC area percentage at which fractions are pooled. The threshold is set by the product specification and the intended use, whether a research reagent, a peptide drug substance, or an intermediate. Pooling at a lower threshold raises yield but risks admitting impure material, and re-purifying a pooled fraction that fails specification costs a full chromatography cycle.
When standard RP-HPLC does not deliver the target purity, the first response is to change the system, not abandon it. Alternative solvents, buffers, or column packing materials alter selectivity. C18-modified silica is the default, but packings such as C4, C8, or polymer-based phases behave differently, and less polar peptides in particular often purify better on a less hydrophobic packing or with a different organic modifier. RP-HPLC is a family of conditions, and a peptide that fails on one member can succeed on another.
Some peptides do not purify well on reversed-phase silica. Very hydrophobic peptides can bind irreversibly or elute as broad aggregated bands, and very polar peptides may be barely retained. For these, and for peptides made by solution-phase synthesis, countercurrent distribution CCD remains in use. Figure 12 of the technical series on which this article draws illustrates the setup: a train of vessels in which the peptide partitions between two immiscible liquid phases, usually an aqueous buffer and an organic solvent, with the upper phase repeatedly transferred against the lower. Separation rests on the partition coefficient, the ratio of solute concentrations in the two phases. A component's position after a given number of transfers follows a predictable distribution, and components separate when their coefficients differ enough; because the entire train is available, a wide range of coefficients can be accommodated in one run. There is no solid stationary phase, so nothing adsorbs the peptide irreversibly and nothing fouls.
CCD is often chosen for peptides synthesized in solution and may be more suitable for large-scale synthesis, particularly when the crude product is of poor quality, because the technique tolerates messy mixtures and high loading. Its costs are time and labor. Each transfer requires the two phases to equilibrate, resolving components with similar partition coefficients can demand many transfers, and the recovered fractions still need analytical HPLC checking and lyophilization. The evidence base is thin: the claims rest on practice and a figure reference rather than on published head-to-head data, and no indexed study supplied here compares CCD with RP-HPLC on defined peptide crudes.
MCSGP , multicolumn countercurrent solvent gradient purification, is the process-scale alternative that has gained the most attention in peptide manufacturing. The process scheme, shown in figure 13 of the technical series, divides the chromatogram into four stream categories: pure product, weakly adsorbing impurities, strongly adsorbing impurities, and overlapping fractions. In conventional single-column batch purification, the overlapping zones, the material between the weakly adsorbing impurity peak and the product peak W/P , and between the product peak and the strongly adsorbing impurity peak P/S , are cut off and discarded or sent to a separate re-run. MCSGP recycles those zones back into the system. Several columns run in a countercurrent arrangement under a solvent gradient, so the impure edges of the product band are re-chromatographed instead of lost, which is the mechanism behind the yield improvement. The product that batch chromatography sacrifices in the cut zones gets a second pass inside the same run, and the solvent that a separate re-purification would consume is never spent.
The manufacturer's comparison against traditional single-column batch purification is specific: solvent consumption falls by over 30% , and yield at target purity is typically 10% higher . The system is automated, operates 24/7 , and shortens cycle time. These are the numbers a process chemist should verify in-house, because they are vendor-provided comparisons and no independent benchmark appears in the indexed literature supplied here.
Deployment information is public at the level of equipment, not results. In 2021 , Bachem, a contract peptide manufacturer, acquired two process-scale MCSGP systems, one for HPLC and one for anion-exchange AEX purification, with column diameters of 20 cm and 30 cm . The company describes the systems as GMP-compliant and reports that they have been used for large-scale purifications. What the public record lacks is the purity and recovery data from those runs: no figures from the 20 cm and 30 cm columns have been published in the sources available here. The description of MCSGP as marking a significant advancement in downstream processing, and the related claim that it promotes greater sustainability, are vendor framing rather than measured outcomes. They should be discounted when evaluating the technology.
The practical question is not which method is best in the abstract but which one fits the peptide, the scale, and the purity target.
| Method | Separation principle | Typical use | Production scale | Main limitation |
|---|---|---|---|---|
| RP-HPLC | Hydrophobicity on C18-modified silica | Default for Fmoc-SPPS crudes | Yes, batch columns | Co-eluting impurities cap purity and cut yield |
| CCD | Partition between two immiscible liquid phases | Solution-phase peptides; poorly soluble or aggregating sequences | Possible | Slow, labor-intensive, large solvent volumes |
| MCSGP | Countercurrent gradient with recycle of overlapping fractions | Runs where yield and solvent cost dominate | Yes, automated 24/7 | Higher capital cost; vendor-only performance data |
A workable sequence for a manufacturer, or for a buyer auditing a supplier:
The indexed literature on peptide purification is dominated by the recombinant route. Affinity tags, in epitope and protein or domain forms, can purify single proteins and multi-protein complexes when used in tandem PMID 32504500 . Aggregating tags offer column-free purification and can match His-tag yield and purity, though the review calls for more systematic testing PMID 26556016 . Peptide affinity purification of antibodies is operationally exacting: continuous-flow serum application improves antibody yield over gravity cycling, and washing requires at least 20 column volumes PMID 31043562 . None of this addresses the manufacturer's question of how to purify an SPPS crude. The comparison among RP-HPLC, CCD, and MCSGP given here rests on a manufacturer's technical series, not on peer-reviewed benchmarks, and the MCSGP performance claims deserve an independent test before they are written into a process design.
What remains unresolved:
A final provenance note: this account draws on the fifth of ten installments in a peptide manufacturer's technical series. The series position signals that the guidance was written by a producer with process experience, and also by a company with products to sell. The chemistry described is standard and the workflow is sound, but the quantitative MCSGP claims should be treated as vendor data until confirmed independently.
Peptides referenced: GLP-1.
Vendors referenced: Polar Peptides.
Related reading: Peptide Storage and Reconstitution: A Practical Stability Guide, Peptide QC After Synthesis: Identity, Purity, and Net Peptide Content, Peptides and Amino Acids: Structure, Classification, and Notation, Chemical Synthesis of Peptides: Protecting Groups and Side Reactions.